Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01707381 · ClinicalTrials.gov registry record · Phase 2
BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension
A Phase 2 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT01707381 is a Phase 2 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 25 participants.
The verdict
NCT01707381, a Phase 2 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
This clinical investigation is being performed to compare the effect of BOL-303259-X dosed once daily (QD) with timolol maleate 0.5% dosed twice daily (BID) in reducing intraocular pressure (IOP) measured over a 24-hour period in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Interventions
- DRUG BOL-303259-X
- DRUG Timolol maleate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2012-11 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01707381
The ClinicalTrials.gov registry entry for NCT01707381 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BOL-303259-X is the first listed.
NCT01707381 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01707381 about?
NCT01707381 is a clinical study titled "BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension". This clinical investigation is being performed to compare the effect of BOL-303259-X dosed once daily (QD) with timolol maleate 0.5% dosed twice daily (BID) in reducing intraocular pressure (IOP) measured over a 24-hour period in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
What is the current status of trial NCT01707381?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2012-11. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01707381?
The interventions under investigation include: BOL-303259-X (DRUG), Timolol maleate (DRUG).
Who is sponsoring clinical trial NCT01707381?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.